Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; CDHF12; PTC), tyrosine-protein kinase receptor UFO (AXL) and vascular endothelial growth factor receptor 2 (VEGFR2; FLK1) inhibitors reported to be useful for the treatment of cancer.

Remegen Ltd. has synthesized antibody-drug conjugates consisting of anti-CDCP1 antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed pyroptosis and NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, gout, inflammatory disorders, multiple sclerosis, psoriasis, autoimmune diseases and Alzheimer’s disease.

Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Dana-Farber Cancer Institute Inc. has divulged tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists reported to be useful for the treatment of inflammation and neuroinflammation.

Elasmogen Ltd. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.

Innatus Therapeutics (Shanghai) Co. Ltd. has synthesized integrin β2 regulators reported to be useful for the treatment of alopecia areata, gouty arthritis, autoimmune hepatitis, inflammatory bowel disease, peritonitis, rheumatoid arthritis, Sjögren’s disease and systemic lupus erythematosus, among others.

Haisco Pharmaceutical Group Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to antitumor drugs through a linker reported to be useful for the treatment of cancer.

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin receptor antagonists reported to be useful for the treatment of neurological disorders.

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.